Yesafili gains traction for DME

Retina drugs are one of those markets where “approved” and “in use” can be very different things. That is the gap around Yesafili right now. The drug — aflibercept-jbvf from Biocon Biologics — already has FDA approval as an interchangeable biosimilar to Eylea, including for diabetic macular edema, or DME. But the real story is that aflibercept biosimilars are finally getting close enough to launch that retina clinics may have to rethink how they buy and choose anti-VEGF treatment. (fda.gov) ### What is Yesafili, exactly? Yesafili is a biosimilar version of aflibercept 2 mg, the same active molecule used in Eylea. In the eye, aflibercept blocks VEGF, a signal that drives leaky blood vessels and swelling in the retina. That matters in DME because the whole point of trea(fda.gov)tem. (fda.gov) ### Why does DME matter here? DME is one of the biggest real-world uses for anti-VEGF injections. These patients often need repeated treatment over months or years, so small changes in price, coverage, and clinic workflow can add up fast. The Yesafili label mirrors Eylea’s DME dosing — monthly for the first 5 injections, then every 8 weeks after that — which is exactly why a biosimilar can matter operationally, not just scientifically. (accessdata.fda.gov) ### What changed? The first big change happened on May 17, 2024, when FDA approved Yesafili and Opuviz as the first interchangeable biosimilars to Eylea. The second big change came later, when Biocon and Regeneron settled patent litigation and set a U.S. market-entry path for Yesafili in the second half of 2026, with broader global commercialization also cleared in (accessdata.fda.gov)w legally real.” (fda.gov) ### Why wasn’t approval enough? Because retina drugs live inside a messy stack of patents, reimbursement rules, and clinic logistics. A biosimilar can be fully approved and still not show up in a physician’s hands if the patent fight is unresolved or the launch date is contractually delayed. That is what made aflibercept biosimilars feel theoretical for a while. The science was there, but the commercial start line was still blocked. (ophthalmologytimes.com) ### What does “interchangeable” really buy? It helps, but maybe less than people assume in retina. Interchangeability means the biosimilar meets extra standards tied to substitutability. In a retail pharmacy, that can be a huge deal. But intravitreal drugs are usually buy-and-bill products handl(ophthalmologytimes.com) pharmacy counter. That is the catch. (fda.gov) ### So what will clinics actually care about? Three things — price, packaging, and friction. If a biosimilar comes with a meaningful discount, predictable supply, and a presentation that fits existing injection workflow, adoption gets easier. If reimbursement is awkward or a clinic(fda.gov)ll, and inject. (pharmacytimes.com) ### Is Yesafili the only aflibercept biosimilar in play? No. Opuviz also won interchangeable approval, and other aflibercept biosimilars have been advancing too. But launch timing matters. Ophthalmology is not just a race to approval — it is a race to actual shelf presence. Right now, Yesafili’s significance is that it is one of the products closest to turning aflibercept biosimilars from a regulatory milestone into a real procurement choice for DME care. (fda.gov) ### Bottom line? Yesafili is not important because it exists on paper. It is important because aflibercept biosimilars are getting close enough to market that DME treatment decisions may start shifting from molecule preference to coverage, contracts, and clinic workflow. That is when a biosimilar stops being a headline and starts changing practice. (ophthalmologytimes.com)